Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells 24,042 Shares of Company Stock

Posted by Brian Himes on Oct 26th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) Director James Foster sold 24,042 shares of the stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the transaction, the director owned 31,596 shares in the company, valued at approximately $11,058,600. This trade represents a 43.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

CRL traded up $11.39 during trading on Monday, hitting $356.76. The stock had a trading volume of 1,172,834 shares, compared to its average volume of 947,519. The firm has a market cap of $17.03 billion, a PE ratio of -73.56, a P/E/G ratio of 3.23 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $146.20 and a 12 month high of $357.77. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a 50 day simple moving average of $294.35 and a 200-day simple moving average of $233.67.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CRL. Royal Bank Of Canada increased their target price on Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Morgan Stanley increased their price objective on Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Finally, Mizuho raised their price objective on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $302.33.

View Our Latest Stock Report on Charles River Laboratories International

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Physician Wealth Advisors Inc. lifted its position in shares of Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after acquiring an additional 55 shares during the period. Continuum Advisory LLC bought a new stake in shares of Charles River Laboratories International during the second quarter valued at approximately $30,000. IFP Advisors Inc raised its stake in shares of Charles River Laboratories International by 182.8% in the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 106 shares in the last quarter. Compass Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the third quarter valued at $69,000. Finally, Activest Wealth Management lifted its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.